Citi upgraded Becton Dickinson to Buy from Neutral with a price target of $275, up from $255. The firm says Becton shares have been range-bound for years, compressing forward valuation multiples. Yet with the initial fiscal 2025 commentary in hand and the closure of the Critical Care assets from Edwards “providing upward bias to estimates, we wonder if this is not the time to become more constructive on BDX,” the analyst tells investors in a research note. Citi believes the initial “soft” guidance is attainable and gives management “breathing room to beat and raise.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BDX:
- Becton Dickinson announces commercial release of BD Neopak XtraFlow
- Merit Medical price target raised to $103 from $92 at BofA
- Edwards Lifesciences price target lowered to $71 from $82 at Truist
- Edwards Lifesciences price target lowered to $80 from $90 at Wells Fargo
- Election 2024: Where To Put Your Money Ahead of the Vote